IL244995B - A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemia - Google Patents
A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemiaInfo
- Publication number
- IL244995B IL244995B IL244995A IL24499516A IL244995B IL 244995 B IL244995 B IL 244995B IL 244995 A IL244995 A IL 244995A IL 24499516 A IL24499516 A IL 24499516A IL 244995 B IL244995 B IL 244995B
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- pcsk9 inhibitor
- treating hyperlipidemia
- hyperlipidemia
- pcsk9
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361890154P | 2013-10-11 | 2013-10-11 | |
| US201461923103P | 2014-01-02 | 2014-01-02 | |
| US201461955514P | 2014-03-19 | 2014-03-19 | |
| US201462004620P | 2014-05-29 | 2014-05-29 | |
| US201462025104P | 2014-07-16 | 2014-07-16 | |
| EP14306221 | 2014-07-31 | ||
| US201462054571P | 2014-09-24 | 2014-09-24 | |
| EP14306584 | 2014-10-09 | ||
| PCT/US2014/060109 WO2015054619A2 (en) | 2013-10-11 | 2014-10-10 | Use of a pcsk9 inhibitor to treat hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL244995A0 IL244995A0 (en) | 2016-05-31 |
| IL244995B true IL244995B (en) | 2019-12-31 |
Family
ID=52813751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL244995A IL244995B (en) | 2013-10-11 | 2016-04-10 | A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150140002A1 (enExample) |
| EP (2) | EP3689913B1 (enExample) |
| JP (2) | JP6846931B2 (enExample) |
| KR (3) | KR20160062166A (enExample) |
| CN (3) | CN115154599A (enExample) |
| AU (2) | AU2014331754B2 (enExample) |
| CA (1) | CA2926942A1 (enExample) |
| EA (1) | EA037526B1 (enExample) |
| ES (1) | ES2914978T3 (enExample) |
| IL (1) | IL244995B (enExample) |
| MX (3) | MX373298B (enExample) |
| PL (2) | PL3055333T4 (enExample) |
| TW (1) | TWI669131B (enExample) |
| WO (1) | WO2015054619A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| CA2825778A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| TW201534324A (zh) | 2013-06-07 | 2015-09-16 | Sanofi Sa | 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法 |
| US10428157B2 (en) | 2013-11-12 | 2019-10-01 | Sanofi Biotechnology | Dosing regimens for use with PCSK9 inhibitors |
| US20170198059A1 (en) * | 2014-07-14 | 2017-07-13 | Amgen Inc. | Crystalline antibody formulations |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| AU2016248997B2 (en) * | 2015-04-15 | 2019-03-07 | ConcieValve LLC | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
| EA201890519A1 (ru) * | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| KR20190049866A (ko) | 2016-09-20 | 2019-05-09 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 항-ｐｃｓｋ９ 항체 |
| US10600502B2 (en) * | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
| US11325945B2 (en) | 2017-04-12 | 2022-05-10 | Cadila Healthcare Limited | Peptide based PCSK9 vaccine |
| WO2018200489A1 (en) | 2017-04-25 | 2018-11-01 | The Brigham And Women’S Hospital, Inc. | Il-8, il-6, il-1b and tet2 and dnmt3a in atherosclerosis |
| CN107090474A (zh) * | 2017-05-22 | 2017-08-25 | 山东大学 | 一种腹主动脉瘤疾病动物模型的制备方法 |
| WO2018228406A1 (zh) * | 2017-06-14 | 2018-12-20 | 江苏恒瑞医药股份有限公司 | Pcsk9抗体、其抗原结合片段及其医药用途 |
| IL277127B2 (en) * | 2018-03-06 | 2025-11-01 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
| KR20250161677A (ko) | 2018-06-21 | 2025-11-17 | 머크 샤프 앤드 돔 엘엘씨 | Pcsk9 길항제 화합물 |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| JP2023501745A (ja) * | 2019-11-18 | 2023-01-18 | エーディー ファーマシューティカルズ カンパニー，リミティド | 抗ｐｃｓｋ９抗体及びその使用 |
| JP2023506732A (ja) * | 2019-12-10 | 2023-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用 |
| US12577259B2 (en) | 2019-12-20 | 2026-03-17 | Merck Sharp & Dohme Llc | PCSK9 antagonist compounds |
| CN114277032A (zh) * | 2021-12-31 | 2022-04-05 | 华中科技大学同济医学院附属协和医院 | 一种低密度脂蛋白受体基因突变体及其应用 |
| CN116983434B (zh) * | 2023-09-28 | 2024-03-15 | 康霖生物科技（杭州）有限公司 | 用于基因治疗的核酸构建体及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| US8357371B2 (en) * | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA2825778A1 (en) * | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2773111T3 (es) * | 2011-09-16 | 2020-07-09 | Regeneron Pharma | Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a) |
| TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
-
2014
- 2014-10-10 MX MX2016004580A patent/MX373298B/es active IP Right Grant
- 2014-10-10 CN CN202210729601.0A patent/CN115154599A/zh active Pending
- 2014-10-10 EP EP19210918.9A patent/EP3689913B1/en active Active
- 2014-10-10 WO PCT/US2014/060109 patent/WO2015054619A2/en not_active Ceased
- 2014-10-10 AU AU2014331754A patent/AU2014331754B2/en active Active
- 2014-10-10 JP JP2016521604A patent/JP6846931B2/ja active Active
- 2014-10-10 KR KR1020167012099A patent/KR20160062166A/ko not_active Ceased
- 2014-10-10 ES ES19210918T patent/ES2914978T3/es active Active
- 2014-10-10 KR KR1020227011822A patent/KR20220048051A/ko not_active Ceased
- 2014-10-10 US US14/511,975 patent/US20150140002A1/en not_active Abandoned
- 2014-10-10 CA CA2926942A patent/CA2926942A1/en active Pending
- 2014-10-10 KR KR1020237026483A patent/KR20230119045A/ko not_active Ceased
- 2014-10-10 EA EA201690754A patent/EA037526B1/ru unknown
- 2014-10-10 CN CN202210762455.1A patent/CN115192704A/zh active Pending
- 2014-10-10 PL PL14802527T patent/PL3055333T4/pl unknown
- 2014-10-10 CN CN201480066894.2A patent/CN105814085A/zh active Pending
- 2014-10-10 PL PL19210918T patent/PL3689913T3/pl unknown
- 2014-10-10 EP EP14802527.3A patent/EP3055333B1/en active Active
- 2014-10-13 TW TW103135495A patent/TWI669131B/zh active
-
2016
- 2016-04-08 MX MX2020004023A patent/MX2020004023A/es unknown
- 2016-04-08 MX MX2022013172A patent/MX2022013172A/es unknown
- 2016-04-10 IL IL244995A patent/IL244995B/en active IP Right Grant
-
2019
- 2019-08-09 JP JP2019146940A patent/JP6994484B2/ja active Active
-
2020
- 2020-06-02 AU AU2020203636A patent/AU2020203636B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238400A (en) | Triazulophyrazines as brd4 inhibitors for use in cancer treatment | |
| RS67779B1 (sr) | Farmaceutska kompozicija, postupci za lečenje i njihova primena | |
| ZA201506487B (en) | Therapeutic compounds and compositions | |
| EP2999691A4 (en) | Cryopyrin inhibitors for preventing and treating inflammation | |
| EP2950884A4 (en) | COMPOSITIONS AND METHOD FOR TREATING SURFACES | |
| SI3086781T1 (sl) | Farmacevtski sestavek zaviralca dpp-iv v kombinaciji z metforminom | |
| IL240553A0 (en) | il-1ß inhibitory compounds and use thereof | |
| IL242584B (en) | An immunogenic preparation for use in treatment | |
| IL278109B (en) | A preparation containing phenoxypropyl amine compounds for use in the treatment or improvement of sleep disorders | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| IL271456B (en) | Pharmaceutical composition comprising pcsk9 inhibitor for use in treating hyperlipidemia | |
| SG11201600119PA (en) | Compound and methods for treating long qt syndrome | |
| ZA201507015B (en) | Composition for treating hemorrhoids | |
| LT2863931T (lt) | Kompozicijos, skirtos panaudoti žaizdų gydymui | |
| IL239872A0 (en) | Metriptase inhibitors and pharmaceutical preparations containing them | |
| LT2863932T (lt) | Kompozicija, skirta naudoti limfedemos gydymui | |
| SG11201507720PA (en) | Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor | |
| ZA201408732B (en) | Composition and methods for treating wounds | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis | |
| ZA201508585B (en) | Immunogenic composition for use in therapy | |
| GB201304675D0 (en) | Novel compositions having use in therapy | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors | |
| EP2961404A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS IN PATIENTS RESPONDING TO TREATMENT | |
| GB201305503D0 (en) | Inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |